Lv4
660 积分 2023-07-19 加入
CAR-T cell therapy for patients with extramedullary multiple myeloma：Opportunities and challenges
20天前
已完结
MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk
1个月前
已完结
Optimizing the timing of lymphocyte collection after stem cell harvesting in B-cell lymphoma and myeloma patients
1个月前
已关闭
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
1个月前
已完结
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
1个月前
已完结
Original communication on a natural phosphocalcic complex of logical and real assimilation, the original preparation D. 52
3个月前
已关闭
A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma
3个月前
已完结
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
4个月前
已完结
Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma
4个月前
已完结
Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates
5个月前
已完结
皖公网安备34019202002308
